KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Long-Term Deferred Tax: 2021-2024

Historic Long-Term Deferred Tax for Halozyme Therapeutics (HALO) over the last 4 years, with Dec 2024 value amounting to $3.9 million.

  • Halozyme Therapeutics' Long-Term Deferred Tax was N/A to $20.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $20.2 million, marking a year-over-year change of. This contributed to the annual value of $3.9 million for FY2024, which is 12.11% down from last year.
  • As of FY2024, Halozyme Therapeutics' Long-Term Deferred Tax stood at $3.9 million, which was down 12.11% from $4.4 million recorded in FY2023.
  • Over the past 5 years, Halozyme Therapeutics' Long-Term Deferred Tax peaked at $155.4 million during FY2021, and registered a low of $3.9 million during FY2024.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $4.4 million (2023), whereas its average is $17.6 million.
  • Data for Halozyme Therapeutics' Long-Term Deferred Tax shows a maximum YoY tumbled of 90.13% (in 2023) over the last 5 years.
  • Over the past 4 years, Halozyme Therapeutics' Long-Term Deferred Tax (Yearly) stood at $155.4 million in 2021, then plummeted by 71.42% to $44.4 million in 2022, then crashed by 90.13% to $4.4 million in 2023, then declined by 12.11% to $3.9 million in 2024.